MarketPulse

efgartigimod

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial